In a phase 3 study population of patients with PPD (N = 90), LPCN 1154 did not demonstrate a statistically significant reduction from baseline in the HAM-D17 total score at 60 hours (primary endpoint) compared to placebo. The primary endpoint was not met In a post hoc analysis of participants (n = 54) with a … Read more
Praxis Precision Medicines, Inc. FDA has set a PDUFA target date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Praxis Precision MedicineInc. (NASDAQ: PRAX), a fully integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has accepted for priority review its New … Read more
The World Health Organization (WHO) is reporting a major shift in how countries respond to the health needs of migrants and refugees, with new data showing more than 60 countries – two-thirds of those surveyed – now include them in their national health policies and laws. Gathering data from 93 Member States, the report forms … Read more